Merck
3Q Revenues: $10.3 billion (-2%)
3Q Loss: $56.0 million (earnings were $2.2 billion 3Q16)
YTD Revenues: $29.7 billion (flat)  
YTD Earnings: $3.5 billion (-24%)   
Comments: Pharmaceutical sales were down 3% to $9.2 billion in the quarter. Keytruda achieved sales of $1.0 billion, up 194% with new indications launched globally. Januvia sales were down 2% to $1.5 billion primarily due to pricing pressure partially offset by volume growth globally. Gardasil sales were down 22% to $675 million. PROQUAD, M-M-R II and VARIVAX sales were $519 million, up 4%. Zepatier sales were up 185% to $468 million. ZETIA / VYTORIN sales were down 51% to $462 million due to the loss of U.S. market exclusivity. ISENTRESS / ISENTRESS HD sales were down 17% to $310 million. ZOSTAVAX sales were up 23% to $234 million. Revenues in the quarter were reduced by approximately $240 million due to a borrowing from the U.S. CDC and Prevention Pediatric Vaccine Stockpile of GARDASIL 9, driven in part by the temporary production shutdown resulting from the cyber-attack, which unfavorably impacted revenues by approximately $135 million from lost sales in certain markets. Loss in the quarter reflects a $2.4 billion charge related to the formation of a strategic oncology collaboration with AstraZeneca.